Evidence map›Paper›PMID 34484233›Full record

ReviewFrontiers in immunology2021

Immunoregulatory Functions of Interferons During Genital HSV-2 Infection.

Emily Feng, Elizabeth Balint, Fatemah Vahedi, Ali A Ashkar

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. The role ofFrontiers in immunology · 2026
    Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Superior antiviral activity of IFNβ in genital HSV-1 infection.Frontiers in cellular and infection microbiology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Emily FengMcMaster Immunology Research Centre, Department of Medicine, McMaster University, Hamilton, ON, Canada.
Elizabeth BalintMcMaster Immunology Research Centre, Department of Medicine, McMaster University, Hamilton, ON, Canada.
Fatemah VahediMcMaster Immunology Research Centre, Department of Medicine, McMaster University, Hamilton, ON, Canada.
Ali A AshkarMcMaster Immunology Research Centre, Department of Medicine, McMaster University, Hamilton, ON, Canada.

Funding

CIHR
6 · The paper itself

Abstract

Herpes simplex virus type 2 (HSV-2) infection is one of the most prevalent sexually transmitted infections that disproportionately impacts women worldwide. Currently, there are no vaccines or curative treatments, resulting in life-long infection. The mucosal environment of the female reproductive tract (FRT) is home to a complex array of local immune defenses that must be carefully coordinated to protect against genital HSV-2 infection, while preventing excessive inflammation to prevent disease symptoms. Crucial to the defense against HSV-2 infection in the FRT are three classes of highly related and integrated cytokines, type I, II, and III interferons (IFN). These three classes of cytokines control HSV-2 infection and reduce tissue damage through a combination of directly inhibiting viral replication, as well as regulating the function of resident immune cells. In this review, we will examine how interferons are induced and their critical role in how they shape the local immune response to HSV-2 infection in the FRT.

Indexed as

AnimalsFemaleHerpes GenitalisHerpesvirus 2, HumanHumansImmunity, MucosalInterferonsMiceMucous MembraneInterferonsfemale reproductive tract (FRT)genital mucosaHSV – 2immune regulationtype III interferonstype II interferontype I interferon (IFN)

Identifiers

PMID34484233
PMCPMC8416247

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.